-
1
-
-
77954657625
-
A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: Incidence and molecular distribution of GIST in a European region
-
20588273 10.1038/sj.bjc.6605743 1:STN:280:DC%2BC3cnmvVahsg%3D%3D
-
Cassier PA, Ducimetiere F, Lurkin A, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer. 2010;103:165-70.
-
(2010)
Br J Cancer
, vol.103
, pp. 165-170
-
-
Cassier, P.A.1
Ducimetiere, F.2
Lurkin, A.3
-
2
-
-
0035142836
-
Gastrointestinal stromal tumors - Definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis
-
11213830 10.1007/s004280000338 1:CAS:528:DC%2BD3MXlt1Kquw%3D%3D
-
Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1-12.
-
(2001)
Virchows Arch.
, vol.438
, pp. 1-12
-
-
Miettinen, M.1
Lasota, J.2
-
3
-
-
15644363454
-
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
-
9438854 10.1126/science.279.5350.577 1:CAS:528:DyaK1cXotVyhsw%3D%3D
-
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-80.
-
(1998)
Science
, vol.279
, pp. 577-580
-
-
Hirota, S.1
Isozaki, K.2
Moriyama, Y.3
-
4
-
-
0242670019
-
PDGFRA activating mutations in gastrointestinal stromal tumors
-
12522257 10.1126/science.1079666 1:CAS:528:DC%2BD3sXntFWitQ%3D%3D
-
Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-10.
-
(2003)
Science
, vol.299
, pp. 708-710
-
-
Heinrich, M.C.1
Corless, C.L.2
Duensing, A.3
-
5
-
-
84855927262
-
The management of gastrointestinal stromal tumors: A model for targeted and multidisciplinary therapy of malignancy
-
22017446 10.1146/annurev-med-043010-091813 1:CAS:528:DC%2BC38Xisleksbo%3D
-
Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med. 2012;63:247-58.
-
(2012)
Annu Rev Med.
, vol.63
, pp. 247-258
-
-
Joensuu, H.1
Dematteo, R.P.2
-
6
-
-
33749459756
-
Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis
-
17090188 1:CAS:528:DC%2BD28XhtFyhs7%2FN
-
Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466-78.
-
(2006)
Arch Pathol Lab Med.
, vol.130
, pp. 1466-1478
-
-
Miettinen, M.1
Lasota, J.2
-
7
-
-
71449088757
-
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: A retrospective analysis
-
19793678 10.1016/S1470-2045(09)70242-6
-
Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045-52.
-
(2009)
Lancet Oncol.
, vol.10
, pp. 1045-1052
-
-
Gold, J.S.1
Gonen, M.2
Gutierrez, A.3
-
8
-
-
80054971913
-
Natural history of imatinib-naive GISTs: A retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables
-
21997685 10.1097/PAS.0b013e31822d63a7
-
Rossi S, Miceli R, Messerini L, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol. 2011;35:1646-56.
-
(2011)
Am J Surg Pathol.
, vol.35
, pp. 1646-1656
-
-
Rossi, S.1
Miceli, R.2
Messerini, L.3
-
9
-
-
65949085379
-
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients
-
19351841 10.1158/0008-5472.CAN-08-3807 1:CAS:528:DC%2BD1MXksV2ht7o%3D
-
Menard C, Blay JY, Borg C, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009;69:3563-9.
-
(2009)
Cancer Res.
, vol.69
, pp. 3563-3569
-
-
Menard, C.1
Blay, J.Y.2
Borg, C.3
-
10
-
-
79958118266
-
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
-
21552268 10.1038/nm.2366 1:CAS:528:DC%2BC3MXlvVagtrk%3D
-
Delahaye NF, Rusakiewicz S, Martins I, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 2011;17:700-7.
-
(2011)
Nat Med.
, vol.17
, pp. 700-707
-
-
Delahaye, N.F.1
Rusakiewicz, S.2
Martins, I.3
-
11
-
-
80052493233
-
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
-
21873989 10.1038/nm.2438 1:CAS:528:DC%2BC3MXhtV2gtLnE
-
Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094-100.
-
(2011)
Nat Med.
, vol.17
, pp. 1094-1100
-
-
Balachandran, V.P.1
Cavnar, M.J.2
Zeng, S.3
-
12
-
-
84655160810
-
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
-
22018713 10.1016/j.ejca.2011.09.001 1:CAS:528:DC%2BC38XhtVCitw%3D%3D
-
Keizman D, Ish-Shalom M, Huang P, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 2012;48:202-8.
-
(2012)
Eur J Cancer.
, vol.48
, pp. 202-208
-
-
Keizman, D.1
Ish-Shalom, M.2
Huang, P.3
-
13
-
-
78650389810
-
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy
-
20956618 10.1158/1078-0432.CCR-10-2245 1:CAS:528:DC%2BC3cXhsFamtLvN
-
Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010;16:5805-13.
-
(2010)
Clin Cancer Res.
, vol.16
, pp. 5805-5813
-
-
Kao, S.C.1
Pavlakis, N.2
Harvie, R.3
-
14
-
-
54849431185
-
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
-
18414853 10.1007/s00262-008-0516-3 1:CAS:528:DC%2BD1cXht1yqs7bO
-
Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58:15-23.
-
(2009)
Cancer Immunol Immunother.
, vol.58
, pp. 15-23
-
-
Cho, H.1
Hur, H.W.2
Kim, S.W.3
-
15
-
-
60449118650
-
Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy
-
19130139 10.1245/s10434-008-0267-6
-
Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009;16:614-22.
-
(2009)
Ann Surg Oncol.
, vol.16
, pp. 614-622
-
-
Kishi, Y.1
Kopetz, S.2
Chun, Y.S.3
Palavecino, M.4
Abdalla, E.K.5
Vauthey, J.N.6
-
16
-
-
43049133286
-
The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer
-
18424885 10.1159/000127412
-
Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007;73:215-20.
-
(2007)
Oncology.
, vol.73
, pp. 215-220
-
-
Yamanaka, T.1
Matsumoto, S.2
Teramukai, S.3
Ishiwata, R.4
Nagai, Y.5
Fukushima, M.6
-
17
-
-
24944529613
-
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study
-
16110036 10.1200/JCO.2005.11.601
-
Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005;23:5795-804.
-
(2005)
J Clin Oncol.
, vol.23
, pp. 5795-5804
-
-
Van Glabbeke, M.1
Verweij, J.2
Casali, P.G.3
-
18
-
-
39149127634
-
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
-
18235122 10.1200/JCO.2007.13.4452 1:CAS:528:DC%2BD1cXis1alsLs%3D
-
Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626-32.
-
(2008)
J Clin Oncol.
, vol.26
, pp. 626-632
-
-
Blanke, C.D.1
Rankin, C.2
Demetri, G.D.3
-
19
-
-
34447536160
-
Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)
-
17458563 10.1007/s00432-007-0202-4 1:CAS:528:DC%2BD2sXnsl2gtLY%3D
-
Rutkowski P, Nowecki ZI, Debiec-Rychter M, et al. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol. 2007;133:589-97.
-
(2007)
J Cancer Res Clin Oncol.
, vol.133
, pp. 589-597
-
-
Rutkowski, P.1
Nowecki, Z.I.2
Debiec-Rychter, M.3
-
20
-
-
77949898532
-
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients
-
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)
-
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28:1247-53.
-
(2010)
J Clin Oncol.
, vol.28
, pp. 1247-1253
-
-
-
21
-
-
2542462086
-
Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
-
15161681 10.1158/1078-0432.CCR-03-0715 1:CAS:528:DC%2BD2cXkt1Ghs70%3D
-
Antonescu CR, Viale A, Sarran L, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res. 2004;10:3282-90.
-
(2004)
Clin Cancer Res.
, vol.10
, pp. 3282-3290
-
-
Antonescu, C.R.1
Viale, A.2
Sarran, L.3
-
22
-
-
33750618188
-
Gastrointestinal stromal tumors: Pathology and prognosis at different sites
-
17193820 10.1053/j.semdp.2006.09.001
-
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70-83.
-
(2006)
Semin Diagn Pathol.
, vol.23
, pp. 70-83
-
-
Miettinen, M.1
Lasota, J.2
-
23
-
-
79955472508
-
Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors
-
21140451 10.1002/ijc.25836 1:CAS:528:DC%2BC3MXltVygsbk%3D
-
Perez D, Hauswirth F, Jager D, et al. Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors. Int J Cancer. 2011;128:2947-52.
-
(2011)
Int J Cancer.
, vol.128
, pp. 2947-2952
-
-
Perez, D.1
Hauswirth, F.2
Jager, D.3
-
24
-
-
50549093386
-
Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence
-
18646188 10.1002/ijc.23698 1:CAS:528:DC%2BD1cXhtV2ru7%2FM
-
Perez D, Herrmann T, Jungbluth AA, et al. Cancer testis antigen expression in gastrointestinal stromal tumors: new markers for early recurrence. Int J Cancer. 2008;123:1551-5.
-
(2008)
Int J Cancer.
, vol.123
, pp. 1551-1555
-
-
Perez, D.1
Herrmann, T.2
Jungbluth, A.A.3
-
25
-
-
25144493776
-
Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: A prognostic model
-
16052222 10.1038/sj.bjc.6602702 1:CAS:528:DC%2BD2MXmvFensLg%3D
-
Schmidt H, Bastholt L, Geertsen P, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93:273-8.
-
(2005)
Br J Cancer.
, vol.93
, pp. 273-278
-
-
Schmidt, H.1
Bastholt, L.2
Geertsen, P.3
-
26
-
-
0037428774
-
Metastatic renal carcinoma comprehensive prognostic system
-
12569375 10.1038/sj.bjc.6600768 1:STN:280:DC%2BD3s7gtlyntA%3D%3D
-
Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88:348-53.
-
(2003)
Br J Cancer.
, vol.88
, pp. 348-353
-
-
Atzpodien, J.1
Royston, P.2
Wandert, T.3
Reitz, M.4
-
27
-
-
3242711105
-
Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma
-
15088127 10.1007/s00262-004-0525-9 1:CAS:528:DC%2BD2cXltF2hsrk%3D
-
Donskov F, Bennedsgaard KM, Hokland M, et al. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother. 2004;53:729-39.
-
(2004)
Cancer Immunol Immunother.
, vol.53
, pp. 729-739
-
-
Donskov, F.1
Bennedsgaard, K.M.2
Hokland, M.3
-
28
-
-
0036739439
-
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie
-
12196373 10.1093/annonc/mdf257 1:STN:280:DC%2BD38vjvVGitA%3D%3D
-
Negrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol. 2002;13:1460-8.
-
(2002)
Ann Oncol.
, vol.13
, pp. 1460-1468
-
-
Negrier, S.1
Escudier, B.2
Gomez, F.3
-
29
-
-
67649304466
-
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03
-
19231158 10.1016/j.ejca.2009.01.023
-
Teramukai S, Kitano T, Kishida Y, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009;45:1950-8.
-
(2009)
Eur J Cancer.
, vol.45
, pp. 1950-1958
-
-
Teramukai, S.1
Kitano, T.2
Kishida, Y.3
-
30
-
-
84856679198
-
Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients
-
21638095 10.1245/s10434-011-1814-0
-
Azab B, Bhatt VR, Phookan J, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19:217-24.
-
(2012)
Ann Surg Oncol.
, vol.19
, pp. 217-224
-
-
Azab, B.1
Bhatt, V.R.2
Phookan, J.3
-
31
-
-
79953672266
-
Polymorphonuclear neutrophils and cancer: Intense and sustained neutrophilia as a treatment against solid tumors
-
19967776 10.1002/med.20185 1:CAS:528:DC%2BC3MXksVKlsLo%3D
-
Souto JC, Vila L, Bru A. Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev. 2011;31:311-63.
-
(2011)
Med Res Rev.
, vol.31
, pp. 311-363
-
-
Souto, J.C.1
Vila, L.2
Bru, A.3
-
33
-
-
62849096370
-
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial
-
19303137 10.1016/S0140-6736(09)60500-6 1:CAS:528:DC%2BD1MXjslOltro%3D
-
Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097-104.
-
(2009)
Lancet.
, vol.373
, pp. 1097-1104
-
-
Dematteo, R.P.1
Ballman, K.V.2
Antonescu, C.R.3
|